78 results about "Chenodeoxycholic acid" patented technology

The invention discloses a method for extracting bilirubin, cholic acid and chenodeoxycholic acid from chicken bile. The method comprises the steps of pretreatment, chicken bile treatment, hydrolysis reduction, chromatographic separation and the like. The method comprises the following steps: slicing frozen chicken gallbladder, heating, unfreezing and melting to denature protein into solid, then cooling, performing three-phase centrifugal degreasing and deproteinization, and adding three enzymes including biliverdin reductase, coenzyme I and glucose dehydrogenase to reduce free biliverdin and combined biliverdin, so as to obtain the biliverdin-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase-free biliverdin-glucose dehydrogenase. The method comprises the following steps: adding cholic acid and chenodeoxycholic acid into a container, adding gluconic acid hydrolase and bile salt hydrolase to hydrolyze biliverdin and bile acid, adding trypsin to hydrolyze impure protein, performing chromatography by using macroporous silica gel, and separating bilirubin, cholic acid and chenodeoxycholic acid by using different molecular space structures to obtain high-purity bilirubin, cholic acid and chenodeoxycholic acid. The method has the advantages of simple process, few types of used solvents, low toxicity, and facilitation of environmental protection and industrial production.

The invention relates to application of chenodeoxycholic acid or pharmaceutically acceptable salt thereof in preparation of a medicine for treating acne. The chenodeoxycholic acid disclosed by the invention can be a natural organic compound or a synthetic organic compound, has relatively strong propionibacterium acnes inhibitory activity and a pharmacodynamic effect of resisting lipid secretion, and is used as an active component to be prepared into a pharmaceutical composition for treating acnes together with a pharmaceutically acceptable carrier.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The present invention provides a recombinant Bacillus subtilis engineering strain and its application in the biological preparation of ursodeoxycholic acid, belonging to the field of bioengineering technology. The present invention provides a recombinant Bacillus subtilis engineering strain that simultaneously and efficiently and stably expresses 7α-hydroxysteroid dehydrogenase (7α-HSDH) and 7β-hydroxysteroid dehydrogenase (7β-HSDH). During biosynthesis, chenodeoxycholic acid is used as a substrate and combined with oxidized coenzyme NADP under the action of 7α-HSDH. + , the 7α-hydroxyl group in chenodeoxycholic acid is oxidized to a carbonyl group, and the resulting intermediate 7-keto-lithocholic acid is reduced to ursodeoxycholic acid under the action of 7β-HSDH and NADPH. The recombinant Bacillus subtilis engineered strain can efficiently and stably biosynthesize ursodeoxycholic acid, and greatly reduces the purification work of the product in industrial applications, greatly reducing production costs.

To provide cellular uptake.SOLUTION: The invention provides a bile acid or a pharmaceutically acceptable salt thereof for use in a method for treating the human or animal body, the method comprises administering to the human or animal body a therapeutic compound, where: a. the bile acid is chenodeoxycholic acid or deoxycholic acid; b. optionally, the bile acid is employed in conjunction with EDTA; c. in the method, the bile acid or salt thereof and EDTA are used to enable or enhance intracellular uptake of the therapeutic compound.SELECTED DRAWING: None

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The invention provides an impurity removal method of a chenodeoxycholic acid crude product, which comprises the following steps: dissolving the chenodeoxycholic acid crude product and glucose in a solvent, adding alkali to control the pH value of the system to be 8-10, and adding thiourea to react so as to convert 22-ene-chenodeoxycholic acid impurities into chenodeoxycholic acid. According to the impurity removal method provided by the invention, the 22-ene-chenodeoxycholic acid impurity in chenodeoxycholic acid can be effectively removed without adopting a heavy metal catalyst and the like, and the method is convenient to operate, mild in condition, low in production risk and suitable for large-scale industrial production.

The invention relates to application of taurochenodeoxycholic acid in preparation of a medicine for preventing and treating hypertension. The key effect of the taurochenodeoxycholic acid in prevention and treatment of hypertension is found for the first time, that is, the taurochenodeoxycholic acid can significantly enhance the diastolic function of arteriole of a hypertensive patient, so that the effect of reducing blood pressure is achieved. Therefore, the invention provides a new application of taurochenodeoxycholic acid in preparation of the medicine for preventing and treating hypertension, a new medicine for preventing and treating hypertension is provided clinically, and the taurochenodeoxycholic acid has a good clinical application value and a wide application prospect. The taurochenodeoxycholic acid can be prepared into a medicine, a pharmaceutical composition, food, a health care product or a food additive by utilizing the key effect of the taurochenodeoxycholic acid in hypertension diseases, can be used for treating hypertension diseases including primary hypertension and salt-sensitive hypertension, and has important application value.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

The invention belongs to the field of biology, discloses a variant of 7 alpha-hydroxysteroid dehydrogenase, and aims to improve the catalytic efficiency and stability of catalyzing chenodeoxycholic acid (CDCA) to be converted into UDCA precursor 7-ketolithocholic acid, and particularly, the variant is obtained by carrying out single mutation or multipoint combined mutation on the 93th site, the 94th site, the 96th site, the 146th site, the 150th site, the 155th site, the 188th site, the 189th site, the 190th site, the 195 site, the 195th site, the 196th site, the 196th site, the 195th site, the 195th site, the 195th site, the 196th site, the 199th site, the 200th site, the 204th site and the 249th site

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The invention relates to the technical field of aquaculture feed, in particular to a feed additive for improving ovary color of scylla paramamosain and application of the feed additive. The feed additive is prepared from the following raw material components in parts by mass: 30-60 parts of Chinese wolfberry fruit powder, 10-30 parts of a marigold extract, 2-8 parts of chenodeoxycholic acid and 5-15 parts of vitamin E powder. The additive systematically solves the technical bottlenecks of low absorptivity and unstable deposition of natural pigments in crab bodies through the synergistic effect of all the components. When the feed additive is added into feed for fattening female scylla paramamosain, the ovary redness value can be remarkably increased, the color is rich and natural, and meanwhile, the growth of parent crabs and the development of gonad are promoted. The feed is completely prepared from natural raw materials, is safe, free of residues and controllable in cost, and provides an effective scheme for realizing high-valued and green cultivation of scylla paramamosain'red cream crab '.

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.

This invention relates to the field of traditional Chinese medicine technology, specifically to a composition for clearing heat and detoxifying, protecting the liver and improving eyesight, its pharmaceutical preparation and application. The raw materials of the composition, by weight, include the following components: 10-30 parts ursodeoxycholic acid, 1-5 parts chenodeoxycholic acid, 5-15 parts Lycium barbarum polysaccharide, 5-18 parts betaine, 1-5 parts glycyrrhizic acid, 0.2-5 parts glycyrrhetinic acid, and 1-5 parts glycyrrhizin. This invention combines these components to achieve the effects of clearing heat and detoxifying, protecting the liver and improving eyesight. Pharmacological experiments have demonstrated that it has significant antipyretic effects, prevents and treats eye fatigue, and improves acute liver injury.

The invention discloses a silanization purification method for ursodesoxycholic acid prepared by a biological enzyme method, and belongs to the field of biological pharmacy. According to the method, the whole-cell reaction liquid is used as a purification object, insoluble macromolecular impurities are removed through preliminary impurity removal and high-concentration acetone-water dissolution, the target content of UDCA is 80% or above successfully, and the product is pure white; the method comprises the following steps: carrying out a reaction on a UDCA silanization derivative and-OH by using a silanization reagent, separating the UDCA silanization derivative from other silanization derivatives, and hydrolyzing the UDCA silanization derivative to realize purification of UDCA. The content of CDCA in the final product is effectively controlled to be 0.5% or below, the purity of the UDCA crude product is improved from 53% to 98.5% or above, and the requirements of UDCA bulk drugs are met. The method is simple in process and low in cost, the obtained product is high in purity, the chenodeoxycholic acid impurity content is low, and the chenodeoxycholic acid can be used as a raw material of a pharmaceutical preparation.

The present invention relates to the preparation of pharmaceutical compositions comprising chenodeoxycholic acid (CDCA) is used in the treatment of cerebrotendineous xanthomatosis (CTX), especially in the form of sachet and for pediatric use.

The present invention relates to the field of medicinal chemistry. Specifically disclosed is a use of oxime-based cholic acid (CA) analogs as allosteric agonists for TGR5. In the present invention, CA used as a raw material undergoes a series of reactions to obtain CA intermediates each having an oxime at either or both of positions 7 and 12, and a series of modifications are then carried out on positions 24 and the oximes of these intermediates to obtain CA analogs as represented by formula 1, formula 2, or formula 3. The present invention uses a GloSensor cAMP accumulation assay to test the functional activity and allosteric mechanism of all target compounds on TGR5. Pharmacological results have shown that all synthesized target compounds have relatively good agonistic activity on TGR5 and can positively allosterically regulate the functional activity of chenodeoxycholic acid (CDCA) or lithocholic acid (LCA), that is, the target compounds are all positive allosteric modulators or allosteric agonists for TGR5.

The present invention discloses a 7α-hydroxysteroid dehydrogenase mutant and its application in the synthesis of 7-oxolithocholic acid, belonging to the fields of genetic engineering and biocatalysis technology. By performing site-directed mutagenesis on specific amino acids in the pocket of Brucella melitensis 7α-hydroxysteroid dehydrogenase (Bm7α-HSDH) and combining some advantageous mutations, the present invention obtains mutants with significantly improved thermal stability and catalytic efficiency. In the reaction of catalyzing the synthesis of 7-oxolithocholic acid from the substrate chenodeoxycholic acid, the enzyme activity of the mutant is increased by up to about 45 times at most, the catalytic efficiency is increased by about 122 times, and the T m value can be increased by about 12 °C at most, providing high-quality biocatalysts and precursor compounds for the biocatalytic synthesis of ursodeoxycholic acid and laying a solid research foundation for its industrial production.

This invention provides a 7α-HSDH enzyme mutant and a 7β-HSDH enzyme mutant, their encoding genes, and their applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

The present invention discloses a Jinqian Dantong pharmaceutical combination for postoperative intervention of cholelithiasis and its application, belonging to the field of pharmaceutical technology. The Jinqian Dantong pharmaceutical combination for postoperative intervention of cholelithiasis includes: a Jinqian Dantong composition and chenodeoxycholic acid; the Jinqian Dantong composition includes Glechoma longituba, Lysimachia christinae, Polygonum cuspidatum, Artemisia capillaris, Bupleurum chinense, Taraxacum mongolicum, Cyperus rotundus, Salvia miltiorrhiza, Cassia obtusifolia and Prunus mume. After performing cholecystolithotomy for patients with cholelithiasis, by combining traditional Chinese medicine ingredients (Jinqian Dantong composition) with western medicine (chenodeoxycholic acid) for intervention, the postoperative stone recurrence rate can be reduced and the quality of life of patients can be improved.

The application discloses a preparation method of chenodeoxycholic acid. The method uses 22E-3alpha-acyloxy-7-ketone-cholest-5,22-diene-24-carboxylic acid methyl ester as raw material, and one-pot three-site hydrogenation reduction of an olefinic bond and a carbonyl group is simultaneously carried out under the reduction condition of a metal catalyst to obtain a 5beta-hydrogen-7alpha-hydroxyl intermediate with high selectivity, and then chenodeoxycholic acid is obtained through hydrolysis. The method for preparing chenodeoxycholic acid directly constructs two chiral centers (5beta and 7alpha) through one-step hydrogenation. The reaction has the characteristics of simplicity, high efficiency, safe operation, high stereoselectivity and convenient product purification, can effectively prepare chenodeoxycholic acid, and is suitable for industrialization. The application has wide application prospect.

The invention discloses a kanamycin chenodeoxycholic acid conjugate and its preparation method and application, and relates to the technical field of drug preparation. The preparation method is: 1) acetonitrile and tetrahydrofuran are dissolved in chenodeoxycholic acid solution, 2N-hydroxysuccinimide and dicyclohexylcarbodiimide are added, and the mixture is stirred at room temperature for 16 hours under argon gas conditions; the precipitated solid is collected by filtration to obtain a white solid product A; 2) the white solid product A and kanamycin prepared in step 1) are dissolved in N, N-dimethylformamide, and K2CO3 and water are added thereto, and the mixture is stirred at room temperature for 16 hours under argon gas conditions; the reaction is purified by HPLC to obtain a kanamycin chenodeoxycholic acid conjugate. The antibiotic drug synthesized by the present invention shows significant advantages in combating drug-resistant bacteria.

The invention relates to the technical field of biology, and particularly discloses combined application of chenodeoxycholic acid and an anti-PD-1 inhibitor in cancer resistance. The research finds that the anti-tumor effect can be effectively improved through combined use of chenodeoxycholic acid and an anti-PD-1 inhibitor, and then the application of the combined use of the chenodeoxycholic acid compound and the anti-PD-1 inhibitor in preparation of drugs for treating cancers is provided, the chenodeoxycholic acid compound is chenodeoxycholic acid or pharmaceutically acceptable salt, prodrug and metabolite of chenodeoxycholic acid; in a unit preparation of the medicine, the mass ratio of the chenodeoxycholic acid compound to the anti-PD-1 inhibitor is (2.9-26): 1 on the basis of the mass of the chenodeoxycholic acid and the anti-PD-1 inhibitor. According to the method, the anti-tumor effect can be improved, the drug dosage is reduced, the toxic and side effects are reduced, the occurrence of drug resistance is reduced, and an effective new method is provided for tumor treatment.

The invention provides application of rhizoma smilacis glabrae in preparation of a medicine for treating intestinal flora and / or metabolic disorder caused by hyperuricemia. The application is realized by regulating and controlling the expression level of SUA-associated metabolic markers in serum. The SUA-associated metabolic markers comprise: metabolites positively associated with SUA, wherein the metabolites comprise chenodeoxycholic acid, nutritional cholic acid, 7alpha-hydroxy-3-oxo-4-cholesteric acid and ceramyl ethanolamide; eight metabolites which are in negative correlation with SUA comprise polyterpene alcohol group-beta-D-glucosyl phosphate, docosapentaenoic acid, 5, 8, 11-eicosatrienoic acid, adrenoic acid, diacylglycerol DG (16: 0 / 22: 5), phosphatidylcholine PC (14: 0 / 18: 1), phosphatidylcholine PC (18: 0 / 22: 6) and retinyl ester.

The invention discloses an application of 7 [beta]-hydroxysteroid dehydrogenase (7 [beta]-HSDH) derived from ruminococcus gnavenus (ruminococcus gnavenus) in the treatment of cholestatic diseases, and relates to a preparation method of the 7 [beta]-hydroxysteroid dehydrogenase (7 [beta]-HSDH). Specifically, Escherichia coli Nissle 1917 is taken as a starting strain, a gene which is derived from ruminococcus gnus and is used for coding 7 beta-hydroxysteroid dehydrogenase is knocked in, a gene editing engineering bacterium capable of converting chenodeoxycholic acid into ursodeoxycholic acid is successfully constructed, and the engineering bacterium can be used for treating primary sclerosing cholangitis caused by cholestasis.

The invention relates to the technical field of biological medicine chemical separation, and discloses a separation and purification process of high-purity ursodesoxycholic acid mother liquor, which comprises the following steps: adding alkaline amino acid into the mother liquor containing ursodesoxycholic acid, stirring and dissolving to obtain a water phase system; adding a neutral chiral hydrophobic deep-eutectic solvent formed by complexing L-menthol and long-chain fatty alcohol into the water-phase system, and carrying out mixed extraction; standing for layering, separating to remove an upper-layer oil phase, and collecting a lower-layer water phase; finally, acid is added into the water phase to adjust the pH value, and an ursodesoxycholic acid product is obtained through ultrasonic-assisted crystallization, cleaning and drying. According to the method disclosed by the invention, efficient separation of a target product from chenodeoxycholic acid and lithocholic acid is realized by utilizing the specific hydrophilic anchoring effect of the basic amino acid on ursodeoxycholic acid and cooperating with the chiral hydrophobic recognition effect of the eutectic solvent on impurities. The process is green and environment-friendly, the solvent can be recycled, and the obtained product is high in purity and suitable for industrial application.

This invention discloses the application of *Gastrococcus xanthophylloides* in regulating intestinal bile acid metabolism disorders, including *Gastrococcus xanthophylloides* (… Ruminococcus flavefaciens The application of this invention in the preparation of compositions for regulating intestinal bile acid metabolism disorders, wherein the compositions promote the conversion of primary bile acids to secondary bile acids, wherein the primary bile acids include cholic acid and chenodeoxycholic acid, and the secondary bile acids include deoxycholic acid and lithocholic acid; wherein the intestinal bile acid metabolism disorders include metabolic disorders caused by antibiotics, wherein the antibiotics include one or more of moxifloxacin and metronidazole; wherein the compositions can be health products, pharmaceuticals, or feed; and wherein the active ingredient of the compositions includes xanthospirococcus flavus.

The invention discloses a preparation method of high-purity ursodesoxycholic acid, and belongs to the technical field of biological medicines. The method provided by the invention specifically comprises the following steps: carrying out a catalytic oxidation reaction on chenodeoxycholic acid by using 7 alpha-hydroxysteroid dehydrogenase to generate a 7-ketolithocholic acid intermediate, and then carrying out a catalytic reduction reaction on 7 beta-hydroxysteroid dehydrogenase to generate a crude ursodeoxycholic acid product. Further, the crude ursodesoxycholic acid reacts with a triethylamine reagent to generate ursodesoxycholic acid triethylamine salt, and a part of cell impurities are removed; dropwise adding an acid reagent to hydrolyze ursodesoxycholic acid triethylamine salt; and finally, recrystallizing and refining by using ethyl acetate and ethanol to obtain high-purity ursodesoxycholic acid. The method is simple in process and low in cost, the obtained product is high in purity, few organic reagents are used, environmental pollution is little, and industrial production can be achieved.